Recently, inclisiran, an siRNA targeting PCSK9 in individuals on maximally tolerated statin doses 46 led to a persistent, highly significant lowering of LDLc in treated individuals relative to placebo in a phase 3 study 47 , introducing siRNAs as an attractive therapeutic modality for lipid-lowering therapies.
← all excerpts
Pairwise effects between lipid GWAS genes modulate lipid plasma levels and cellular uptake.
1
—
—